Short Wave
Could Psychedelics Become Tripless?
Apr 9, 2025
Rachel Carlson, a dedicated producer and reporter on psychedelic science, dives into the fascinating world of non-hallucinogenic alternatives to traditional psychedelics. She discusses groundbreaking research on modifying these compounds to retain their therapeutic benefits while eliminating hallucinatory experiences. The conversation explores innovative treatments, such as 'psychoplastogens' and the promising drug DLX1 aimed at tackling conditions like depression. Carlson also highlights the ongoing debates on the necessity of trips in psychedelic therapy, offering a glimpse into the future of mental health treatment.
12:58
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Researchers are focusing on developing non-hallucinogenic psychoplastogens that offer therapeutic benefits while minimizing risks associated with traditional psychedelics.
- The ongoing debate highlights that while new drugs may provide biological improvements, the transformative experience of traditional psychedelics remains crucial for effective therapy.
Deep dives
Advancements in Non-Hallucinogenic Psychedelics
Researchers are exploring the development of non-hallucinogenic drugs inspired by psychedelics, aiming to provide therapeutic effects without the accompanying trip. David Olson, a chemical neuroscientist, co-founded Deluxe Therapeutics, which focuses on modifying existing psychedelic structures to create safer alternatives. This approach could cater to individuals who may not tolerate traditional psychedelics, such as those with bipolar disorder or schizophrenia. The goal is to create medications that promote mental health recovery while minimizing risks associated with hallucinations, potentially making them more accessible.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
